Search Results | Diabetes | American Diabetes Association

1-20 of 57

2 3

Sort by

Sort Order Select

Journal Articles

Crosstalk Between Insulin- and Glucagon-Receptor Signaling in the Hepatocyte

Kirk Habegger

Diabetes dbi220002

DOI: https://doi.org/10.2337/dbi22-0002

Published: 03 June 2022

View article

Meeting Abstracts

340-OR: LY3437943 (LY) , a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment

SHWETA URVA, MEI TENG LOH, TAMER COSKUN, YU DU, CHARLES BENSON, CORINA LOGHIN, AXEL HAUPT, ZVONKO MILICEVIC

Diabetes 2022;71(Supplement_1):340-OR

DOI: https://doi.org/10.2337/db22-340-OR

Published: 01 June 2022

View article

Meeting Abstracts

1332-P: Increased and Decreased Glucagon Receptor Signaling Respectively Enhances and Impairs Triglyceride Metabolism Acutely and Chronically

KATRINE D. GALSGAARD, EMILIE E. CHRISTENSEN, ANNA B. BOMHOLT, JENNA HUNT, THOMAS KRUSE, JESPER F. LAU, CHRISTINA CHRISTOFFERSEN, JENS J. HOLST, NICOLAI J. WEWER ALBRECHTSEN

Diabetes 2022;71(Supplement_1):1332-P

DOI: https://doi.org/10.2337/db22-1332-P

Published: 01 June 2022

View article

Meeting Abstracts

197-OR: Glucagon Receptor Agonism Stimulates Time-Dependent Glycemic Regulation

SHELLY NASON, TEAYOUN KIM, JESSICA P. ANTIPENKO, BRIAN FINAN, RICHARD DIMARCHI, KIRK M. HABEGGER

Diabetes 2022;71(Supplement_1):197-OR

DOI: https://doi.org/10.2337/db22-197-OR

Published: 01 June 2022

View article

Meeting Abstracts

230-OR: Hepatic TORC2 Signaling Facilitates Glucagon-Receptor Enhancement of Insulin-Stimulated Glucose Homeostasis in Mice

TEAYOUN KIM, SHELLY NASON, JESSICA P. ANTIPENKO, BRIAN FINAN, ANATH SHALEV, RICHARD DIMARCHI, KIRK M. HABEGGER

Diabetes 2022;71(Supplement_1):230-OR

DOI: https://doi.org/10.2337/db22-230-OR

Published: 01 June 2022

View article

Meeting Abstracts

667-P: IBI362 (LY3305677), a Weekly-Dose Glucagon-Like Peptide-1/Glucagon Receptor Dual Agonist, in Subjects with Overweight or Obesity

HONGWEI JIANG, PEI AN, HELENA DENG, LI LI, LIQI FENG, QINGYANG MA, LEI QIAN, LINONG JI

Diabetes 2021;70(Supplement_1):667-P

DOI: https://doi.org/10.2337/db21-667-P

Published: 01 June 2021

View article

Meeting Abstracts

674-P: Efficacy and Safety of Cotadutide, a Dual GLP-1 and Glucagon Receptor Agonist in Patients with T2DM and DKD

VICTORIA E. PARKER, THUONG HOANG, HEIKE SCHLICHTHAAR, FRASER W. GIBB, BARBARA WENZEL, MAXIMILIAN G. POSCH, YI-TING CHANG, MARCELLA PETRONE, LARS HANSEN, PHILIP AMBERY, HIDDO L. HEERSPINK, RORY J. MCCRIMMON, LUTZ JERMUTUS

Diabetes 2021;70(Supplement_1):674-P

DOI: https://doi.org/10.2337/db21-674-P

Published: 01 June 2021

View article

Meeting Abstracts

236-OR: Volagidemab, a Human Glucagon Receptor Antagonist, Improves Glycemic Control in Subjects with Type 1 Diabetes (T1D): A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

JEREMY PETTUS, SCHAFER C. BOEDER, MARK P. CHRISTIANSEN, DOUGLAS S. DENHAM, TIMOTHY S. BAILEY, HALIS K. AKTURK, LESLIE J. KLAFF, JULIO ROSENSTOCK, MICKIE H.M. CHENG, BRUCE W. BODE, EDGAR D. BAUTISTA, HAI YAN, DUNG THAI, SATISH K. GARG, SAMUEL KLEIN

Diabetes 2021;70(Supplement_1):236-OR

DOI: https://doi.org/10.2337/db21-236-OR

Published: 01 June 2021

View article

Meeting Abstracts

104-OR: Novel GIP/GLP-1/Glucagon Receptor Agonist LY3437943: A First-in-Human Dose Study in Healthy Subjects

SHWETA URVA, YU DU, MELISSA K. THOMAS, ZVONKO MILICEVIC, TAMER COSKUN, CHARLES BENSON, CORINA LOGHIN

Diabetes 2021;70(Supplement_1):104-OR

DOI: https://doi.org/10.2337/db21-104-OR

Published: 01 June 2021

View article

Meeting Abstracts

115-LB: Liver-Derived FGF21 Mediates the Promoting Effect of Glucagon Receptor Antagonism on Beta-Cell Regeneration in Type 2 Diabetic Mice

XIAONA CUI, TIANJIAO WEI, JIN FENG, JIN YANG, HAI YAN, RUI WEI, TIANPEI HONG

Diabetes 2021;70(Supplement_1):115-LB

DOI: https://doi.org/10.2337/db21-115-LB

Published: 01 June 2021

View article

Journal Articles

The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition

Sofie Hædersdal, Asger Lund, Elisabeth Nielsen-Hannerup, Henrik Maagensen, Gerrit van Hall, Jens J. Holst, Filip K. Knop, Tina Vilsbøll

Diabetes 2020;69(12):2619–2629

DOI: https://doi.org/10.2337/db20-0369

Published: 01 October 2020

View article

Meeting Abstracts

255-OR: ADA Presidents’ Select Abstract: Glucagon Receptor Antagonism Stimulates Beta-Cell Proliferation in Mouse and Human Islets

KATIE C. COATE, ERICK SPEARS, CHUNHUA DAI, SCOTT WISNIEWSKI, GREG POFFENBERGER, LEONARD D. SHULTZ, DALE L. GREINER, DANIEL J. DRUCKER, HAI YAN, KYLE SLOOP, ALVIN C. POWERS, DANIELLE DEAN

Diabetes 2020;69(Supplement_1):255-OR

DOI: https://doi.org/10.2337/db20-255-OR

Published: 01 June 2020

View article

Meeting Abstracts

1813-P: Coadministration of a GLP-1/Glucagon Receptor Agonist with an FXR Agonist and ACC Inhibitor Reverses Nonalcoholic Steatohepatitis (NASH) in Diet-Induced and Biopsy-Confirmed Mice

JAMES L. TREVASKIS, JENNY NORLIN, DIEGO A. MIRANDA, JAMIE G. BATES, NORA E. ZOIS, SANNE VEIDAL, MICHAEL FEIGH, MARKUS LATTA

Diabetes 2020;69(Supplement_1):1813-P

DOI: https://doi.org/10.2337/db20-1813-P

Published: 01 June 2020

View article

Meeting Abstracts

1908-P: Glucagon Receptor Expression Evaluated by Antibody-Dependent and -Independent Approaches

SASHA KJELDSEN, KATRINE D. GALSGAARD, MARIE WINTHER-SOERENSEN, REZA SERIZAWA, JENS PEDERSEN, CATHRINE ORSKOV, REIDAR ALBRECHTSEN, CHARLOTTE M. SORENSEN, LISE GLUUD, JENS J. HOLST, NICOLAI J. WEWER ALBRECHTSEN

Diabetes 2020;69(Supplement_1):1908-P

DOI: https://doi.org/10.2337/db20-1908-P

Published: 01 June 2020

View article

Meeting Abstracts

128-LB: Effects of Glucagon Receptor Antagonism (GRA) on Ketone Body Formation during Insulinopenia in Type 1 Diabetes (T1D)

SCHAFER C. BOEDER, DANIEL G. INES, LESLIE CARTER, ERIN R. GIOVANNETTI, DEBRA ARMSTRONG, PAIVI BURKE, JEREMY PETTUS

Diabetes 2020;69(Supplement_1):128-LB

DOI: https://doi.org/10.2337/db20-128-LB

Published: 01 June 2020

View article

Meeting Abstracts

988-P: MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity, Promotes a Dose-Dependent Increase in Gastric Emptying Time

DARREN ROBERTSON, VICTORIA E. PARKER, PHILIP AMBERY, MARCELLA PETRONE, TAO WANG, TIM HEISE, LEONA PLUM-MOERSCHEL, LUTZ JERMUTUS, BOAZ HIRSHBERG, JURIS J. MEIER

Diabetes 2019;68(Supplement_1):988-P

DOI: https://doi.org/10.2337/db19-988-P

Published: 01 June 2019

View article

Meeting Abstracts

989-P: MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity: Safety Study in Subjects of Japanese and Chinese Descent

DARREN ROBERTSON, MARCELLA PETRONE, LAN-FENG TSAI, ROBERT A. GASSER, JR.

Diabetes 2019;68(Supplement_1):989-P

DOI: https://doi.org/10.2337/db19-989-P

Published: 01 June 2019

View article

Meeting Abstracts

1883-P: Phosphoproteomics Reveals Mechanistic Insight into Glucagon-Mediated Inhibition of Hepatic Lipogenesis and How MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity, Reverses Steatosis

RHIANNA C. LAKER, MICHELLE BOLAND, ARKADIUSZ NAWROCKI, KARLY M. MATHER, LUTZ JERMUTUS, MARTIN R. LARSEN, JAMES TREVASKIS, CHRISTOPHER J. RHODES

Diabetes 2019;68(Supplement_1):1883-P

DOI: https://doi.org/10.2337/db19-1883-P

Published: 01 June 2019

View article

Meeting Abstracts

1870-P: Glucagon-Receptor Signaling Reverses Hepatic Steatosis Independent of Leptin Receptor Expression

SHELLY NASON, TEAYOUN KIM, JESSICA P. ANTIPENKO, BRIAN FINAN, RICHARD DIMARCHI, KIRK M. HABEGGER

Diabetes 2019;68(Supplement_1):1870-P

DOI: https://doi.org/10.2337/db19-1870-P

Published: 01 June 2019

View article

Meeting Abstracts

1952-P: Glucagon Receptor Antagonism Increases Plasma Amino Acids and Glucagon

SOFIE HAEDERSDAL, NICOLAI JACOB WEWER ALBRECHTSEN, ASGER B. LUND, KATRINE D. GALSGAARD, MARIE WINTHER-SOERENSEN, JENS J. HOLST, FILIP K. KNOP, TINA VILSBØLL

Diabetes 2019;68(Supplement_1):1952-P

DOI: https://doi.org/10.2337/db19-1952-P

Published: 01 June 2019

View article

2 3

NARROW

Crosstalk Between Insulin- and Glucagon-Receptor Signaling in the Hepatocyte

340-OR: LY3437943 (LY) , a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment

1332-P: Increased and Decreased Glucagon Receptor Signaling Respectively Enhances and Impairs Triglyceride Metabolism Acutely and Chronically

197-OR: Glucagon Receptor Agonism Stimulates Time-Dependent Glycemic Regulation

230-OR: Hepatic TORC2 Signaling Facilitates Glucagon-Receptor Enhancement of Insulin-Stimulated Glucose Homeostasis in Mice

667-P: IBI362 (LY3305677), a Weekly-Dose Glucagon-Like Peptide-1/Glucagon Receptor Dual Agonist, in Subjects with Overweight or Obesity

674-P: Efficacy and Safety of Cotadutide, a Dual GLP-1 and Glucagon Receptor Agonist in Patients with T2DM and DKD

236-OR: Volagidemab, a Human Glucagon Receptor Antagonist, Improves Glycemic Control in Subjects with Type 1 Diabetes (T1D): A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

104-OR: Novel GIP/GLP-1/Glucagon Receptor Agonist LY3437943: A First-in-Human Dose Study in Healthy Subjects

115-LB: Liver-Derived FGF21 Mediates the Promoting Effect of Glucagon Receptor Antagonism on Beta-Cell Regeneration in Type 2 Diabetic Mice

The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition

255-OR: ADA Presidents’ Select Abstract: Glucagon Receptor Antagonism Stimulates Beta-Cell Proliferation in Mouse and Human Islets

1813-P: Coadministration of a GLP-1/Glucagon Receptor Agonist with an FXR Agonist and ACC Inhibitor Reverses Nonalcoholic Steatohepatitis (NASH) in Diet-Induced and Biopsy-Confirmed Mice

1908-P: Glucagon Receptor Expression Evaluated by Antibody-Dependent and -Independent Approaches

128-LB: Effects of Glucagon Receptor Antagonism (GRA) on Ketone Body Formation during Insulinopenia in Type 1 Diabetes (T1D)

988-P: MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity, Promotes a Dose-Dependent Increase in Gastric Emptying Time

989-P: MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity: Safety Study in Subjects of Japanese and Chinese Descent

1883-P: Phosphoproteomics Reveals Mechanistic Insight into Glucagon-Mediated Inhibition of Hepatic Lipogenesis and How MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity, Reverses Steatosis

1870-P: Glucagon-Receptor Signaling Reverses Hepatic Steatosis Independent of Leptin Receptor Expression

1952-P: Glucagon Receptor Antagonism Increases Plasma Amino Acids and Glucagon

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only